The coronavirus COVID-19 vaccine and progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) will be the topic during a webinar on Monday, January 25, 2021. Dr. Lawrence I. Golbe, Director of Clinical Affairs for CurePSP, will be the presenter at this 30-minute webinar that begins at 2:00 p.m. Eastern Standard Time (11:00 a.m. Pacific).
Dr. Globe, who also serves as chair of CurePSP’s Medical Advisory Board, has written an advisory memo on this subject. PSP, CBD and MSA are conditions that increase the risk of death from Covid-19 and therefore should qualify as underlying conditions warranting priority for receiving a Covid vaccine.
This webinar will be moderated by Joanna Teters, CurePSP’s community outreach and resource manager. Questions can be submitted in advance at firstname.lastname@example.org or through the registration link.
Dr. Golbe will answer questions that were submitted during registration by patients and families. He cannot give case-specific medical advice, and any medications that are mentioned during the webinar should not be tried unless under the supervision of a licensed professional.
The webinar will be set up on the Zoom platform. Registration is required. A link to the webinar will be emailed to registrants twice from Eventbrite before the event: the first will be two hours before the event, and the second ten minutes before.
This webinar will be recorded and emailed to all registrants. Previous Ask to Doctor webinars can be viewed on the CurePSP Youtube channel.
About Dr. Larry I. Golbe
Dr. Golbe is Emeritus Professor of Neurology at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ. He graduated from Brown University and New York University School of Medicine and did residency training at NYU/Bellevue before assuming his current position. He was Acting Chair of the department from 2000 to 2003 and Program Director of its neurology residency from 2003 to 2018.
Dr. Golbe’s research is in the clinical genetics, clinimetrics, and epidemiology of parkinsonian disorders. In 1988 he co-led the first studies of the prevalence and risk factors in PSP. He led the clinical portion of the project that in 1997 identified the first known Mendelian mutation causing Parkinson’s disease in the gene for alpha-synuclein. He devised the PSP Rating Scale, which since its publication in 2007 has become the standard clinical measure and treatment outcome marker for PSP worldwide.
He has a referral practice for patients with PSP and CBD and conducts multiple ongoing research studies. He has worked closely with CurePSP since 1992, presently as Director of Clinical Affairs, chair of its Medical Advisory Board, and a member of its Board of Directors.
CurePSP is a nonprofit organization working to increase awareness, advocate for patients and families, and fund research for devastating prime of life neurodegenerative diseases, including PSP, CBD, and MSA. CurePSP provides advocacy and support for patients, families, and caregivers; education for physicians and allied healthcare professionals; and funding for research.